Information:
Fel:
ID
34308
Beskrivning
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease; ODM derived from: https://clinicaltrials.gov/show/NCT01598740
Länk
https://clinicaltrials.gov/show/NCT01598740
Nyckelord
Versioner (1)
- 2019-01-16 2019-01-16 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
16 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Heart Failure NCT01598740
Eligibility Heart Failure NCT01598740
- StudyEvent: Eligibility
Similar models
Eligibility Heart Failure NCT01598740
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
heart failure with new york heart association (nyha) classification ii or iii
boolean
ID.2
Item
chronic kidney disease
boolean
ID.3
Item
cardiac ejection fraction <40%
boolean
ID.4
Item
on heart failure therapy including an acei or arb, and a bb
boolean
ID.5
Item
willing to understand and comply with study procedures and provide written informed consent.
boolean
ID.6
Item
hospitalization within 4 weeks of baseline visit
boolean
ID.7
Item
history or presence of gastrointestinal conditions such as severe constipation or gastrointestinal tract strictures
boolean
ID.8
Item
current or anticipated dialysis during study
boolean
ID.9
Item
in the investigator's judgment, any cardiovascular, renal, hepatic, endocrine, gastrointestinal, neurological, or other disease or condition that makes the subject's study participation unsafe
boolean
ID.10
Item
drug or alcohol abuse
boolean